|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1196193270 |
| 003 |
OCoLC |
| 005 |
20231120010509.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
200814s2020 ne fob 000 0 eng d |
| 040 |
|
|
|a UKAHL
|b eng
|e rda
|e pn
|c UKAHL
|d UKMGB
|d OCLCO
|d OPELS
|d OCLCO
|d OCLCF
|d EBLCP
|d YDX
|d N$T
|d DKU
|d OCLCO
|d VT2
|d OCLCQ
|d OCLCO
|d OCLCQ
|d CUS
|d CASUM
|d OCLCO
|
| 015 |
|
|
|a GBC0B7152
|2 bnb
|
| 015 |
|
|
|a GBC0B5724
|2 bnb
|
| 016 |
7 |
|
|a 019886966
|2 Uk
|
| 019 |
|
|
|a 1194498588
|a 1195469272
|a 1281712704
|a 1286906662
|
| 020 |
|
|
|a 0128211091
|q (e-book)
|
| 020 |
|
|
|a 9780128211090
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128211083
|q (hbk.)
|
| 020 |
|
|
|z 0128211083
|
| 035 |
|
|
|a (OCoLC)1196193270
|z (OCoLC)1194498588
|z (OCoLC)1195469272
|z (OCoLC)1281712704
|z (OCoLC)1286906662
|
| 050 |
|
4 |
|a RC392
|
| 060 |
|
4 |
|a W1
|b PR667J v.255 2020
|
| 060 |
|
4 |
|a WL 344
|
| 082 |
0 |
4 |
|a 616.8491206
|2 23
|
| 245 |
0 |
0 |
|a Update on emerging treatments for migraine /
|c edited by Shuu-Jiun Wang, Chi Ieong Lau.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Progress in brain research ;
|v 255
|
| 505 |
0 |
|
|a Intro -- Update on Emerging Treatments for Migraine -- Copyright -- Contributors -- Contents -- Preface -- Chapter 1: Update in migraine preventive treatment -- Abstract -- Keywords -- 1. Introduction -- 2. Preventive medications for migraine -- 2.1. Beta-blockers -- 2.2. Antiepileptic drugs -- 2.3. Calcium channel blockers -- 2.4. Antidepressants -- 2.5. Non-steroid anti-inflammatory drugs (NSAIDs) -- 2.6. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) -- 2.7. Miscellaneous -- 3. Preventive medications for chronic migraine -- 3.1. OnabotulinumtoxinA
|
| 505 |
8 |
|
|a 3.2. Topiramate -- 4. Calcitonin gene-related peptide monoclonal antibodies -- 4.1. Erenumab -- 4.2. Galcanezumab -- 4.3. Fremanezumab -- 4.4. Eptinezumab -- 5. Special considerations -- 5.1. Menstrual-related migraine -- 5.2. Pregnancy and breastfeeding -- 5.3. Children and adolescents -- 6. Conclusion -- References -- Chapter 2: Therapeutic implications of cortical spreading depression models in migraine -- Abstract -- Keyword -- 1. Migraine -- 2. Cortical spreading depression -- 3. Basics on in vivo experimental models of CSD -- 4. Consequences of CSD -- 4.1. Trigeminovascular activation
|
| 505 |
8 |
|
|a 4.2. Cortical inflammation -- 4.3. Disruption of blood-brain barrier and impaired glymphatic flow -- 5. Migraine modulators affect CSD susceptibility -- 5.1. Genetic factors -- 5.2. Sex and age -- 5.3. Stress, sleep deprivation and hypoglycemia -- 6. CSD inhibition reflecting clinical responsiveness -- 7. CSD inhibitors that inhibit migraine aura but not headache -- 7.1. Ketamine -- 7.2. Lamotrigine -- 7.3. Tonabersat -- 8. Novel targets for migraine therapeutics -- 8.1. Calcitonin gene-related peptide -- 8.2. Ion channels -- 8.2.1. Pannexin-1 channels and P2X7 receptors
|
| 505 |
8 |
|
|a 8.2.2. Acid-sensing ion channels (ASICs) -- 8.2.3. Transient receptor potential (TRP) channels -- 8.2.4. TWIK-related spinal cord potassium channel (TRESK) -- 8.3. Insulin-like growth factor-1 (IGF-1) -- 8.4. Neuromodulation -- 8.4.1. Vagus nerve stimulation -- 8.4.2. Transcranial magnetic stimulation -- 8.4.3. Transcranial direct current stimulation -- 9. Future directions and potentials for CSD models -- 10. Conclusion -- Funding -- References -- Chapter 3: Electrophysiological basis for antiepileptic drugs in migraine prevention -- Abstract -- Keywords -- 1. Introduction
|
| 505 |
8 |
|
|a 2. Basic concepts of electrophysiological studies in migraine -- 3. The visual cortex -- 3.1. Steady-state visual evoked potential (SSVEP) -- 3.2. Pattern reversal visual evoked potential (PRVEP) -- 3.3. Phosphene induced by transcranial magnetic stimulation -- 3.4. Magnetic suppression of perceptual accuracy (MSPA) -- 4. The somatosensory cortex -- 4.1. Standard (broad-band) somatosensory evoked potential -- 4.2. High-frequency oscillations of the somatosensory evoked potential -- 5. The motor cortex -- 5.1. Motor threshold (MTh) and motor evoked potentials (MEPs) -- 5.2. Silent period (SP)
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 650 |
|
0 |
|a Migraine
|x Treatment.
|
| 650 |
|
2 |
|a Migraine Disorders
|x therapy
|0 (DNLM)D008881Q000628
|
| 650 |
|
6 |
|a Migraine
|0 (CaQQLa)201-0096926
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
7 |
|a Migraine
|x Treatment
|2 fast
|0 (OCoLC)fst01020683
|
| 655 |
|
4 |
|a Internet Resources.
|
| 655 |
|
4 |
|a Index not Present.
|
| 700 |
1 |
|
|a Wang, Shuu-Jiun,
|e editor.
|
| 700 |
1 |
|
|a Lau, Chi leong,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Update on emerging treatments for migraine.
|b First edition.
|d Amsterdam : Elsevier, 2020
|z 0128211083
|w (DLC) 2022304161
|w (OCoLC)1141039606
|
| 830 |
|
0 |
|a Progress in brain research ;
|v 255.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00796123/255
|z Texto completo
|
